Fineline Cube

Follow:
14484 Articles
Blackstone and Bain Capital Submit Final Bids for Mitsubishi Tanabe Pharma
CompanyDeals

Blackstone and Bain Capital Submit Final Bids for Mitsubishi Tanabe Pharma

Everest Medicines' Velsipity NDA for Ulcerative Colitis Accepted by China's NMPA
CompanyDrug

Everest Medicines’ Velsipity NDA for Ulcerative Colitis Accepted by China’s NMPA

AstraZeneca's ALXN2350 Selected for CDE's Rare Disease Drug Development Program
Drug

AstraZeneca’s ALXN2350 Selected for CDE’s Rare Disease Drug Development Program

NMPA's CDE Releases Draft Proposal for Benefit-Risk Assessment in Global Drug Development
Policy / Regulatory

NMPA’s CDE Releases Draft Proposal for Benefit-Risk Assessment in Global Drug Development

Perennial Real Estate Holdings' Tianjin Hospital Earns Medical Practice License
Hospital

Perennial Real Estate Holdings’ Tianjin Hospital Earns Medical Practice License

MSD Halts Development of Vibostolimab and Favezelimab Due to Trial Setbacks
CompanyDrug

MSD Halts Development of Vibostolimab and Favezelimab Due to Trial Setbacks

Adcendo ApS Expands Partnership with Biocytogen to Enhance ADC Pipeline
CompanyDeals

Adcendo ApS Expands Partnership with Biocytogen to Enhance ADC Pipeline

MicroPort CardioFlow's VitaFlow Liberty Receives Marketing Approval in Turkey
CompanyMedical Device

MicroPort CardioFlow’s VitaFlow Liberty Receives Marketing Approval in Turkey

Vcanbio's VUM02 Secures NMPA Approval and FDA ODD for Cirrhosis and aGvHD
CompanyDrug

Vcanbio’s VUM02 Secures NMPA Approval and FDA ODD for Cirrhosis and aGvHD

Novo Nordisk Invests DKK 8.5 Billion in New Odense Manufacturing Facility
Company

Novo Nordisk Invests DKK 8.5 Billion in New Odense Manufacturing Facility

Johnson & Johnson Submits sBLA to FDA for Simponi in Pediatric Ulcerative Colitis
CompanyDrug

Johnson & Johnson Submits sBLA to FDA for Simponi in Pediatric Ulcerative Colitis

J&J's SC Amivantamab Faces Complete Response Letter from FDA for NSCLC Treatment
CompanyDrug

J&J’s SC Amivantamab Faces Complete Response Letter from FDA for NSCLC Treatment